Fundraising Fox
Nkarta, Inc.
NASDAQ: NKTXSouth San Francisco, US · Founded 2015 · 160 employees on LinkedIn · 8 known investors
Find your way into Nkarta, Inc.
Sign up to find every way you can get introduced to Nkarta, Inc.
- Your email: who you already know at Nkarta, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nkarta, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
Founders & leadership
Board
Investors · 8
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: SR One Capital Management's portfolio page · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$43.9M disclosed across 1 of 2 rounds · 1900–2019
▶$43.9MraisedSep 2019 · 13 investors · BiotechnologyRule 506(b)
- Matthew PlunkettExecutive Officer
- Michael DybbsDirector
- Jill CarrollDirector
- Tiba AynechiDirector
- Paul HastingsExecutive Officer, Director
- Fouad AzzamDirector
- Ali BehbahaniDirector
- Offering amount
- $114.6M
- Amount sold
- $43.9M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
Companies working in the same space as Nkarta, Inc..
Frequently asked questions
- What does Nkarta, Inc. do?
- Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
- Who are Nkarta, Inc.'s investors?
- Nkarta, Inc.'s investors include New Enterprise Associates (NEA), RA Capital, Samsara BioCapital, SR One Capital Management, Amgen Ventures, Logos, Norwest Venture Partners, Novo Holdings.
- How much funding has Nkarta, Inc. raised?
- Nkarta, Inc. has disclosed $43.9M raised across 1 of its 2 known rounds.
- Where is Nkarta, Inc. headquartered?
- Nkarta, Inc. is headquartered in South San Francisco, US.